The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | FRONT-BRAF: 1L immunotherapy +/- chemo vs. BRAF + MEK inhibitors in mNSCLC
Alessandro Di Federico, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the FRONT-BRAF study evaluating first-line (1L) immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer (mNSCLC). Results showed targeted therapy achieved higher objective response rates (63% vs 48%), but progression-free survival was similar between groups (11-12 months). Notably, overall survival was significantly longer with first-line immunotherapy at 40 months compared to 25 months with targeted therapy, suggesting immunotherapy may be the preferred initial approach for this rare lung cancer subset. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
